Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 295-302

  Yan, Dongmei ^a   Zheng, Xiaoliang ^a   Tu, Linglan ^a   Jia, Jing ^a   Li, Qin ^a   Cheng, Liyan ^a   Wang, Xiaoju ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antitumor agent; Chemosensitivity; Merm1 Wbscr22; Non small cell lung cancer cell line; P53

Indexed keywords

CISPLATIN; DOXORUBICIN; FIRTECAN; FLUOROURACIL; MESSENGER RNA; MITOMYCIN; PACLITAXEL; PROTEIN P53; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; IRINOTECAN; METHYLTRANSFERASE; WBSCR22 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MERM1 GENE; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; STABLE TRANSFECTION; TUMOR XENOGRAFT; WBSCR22 GENE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG TUMOR; REPRODUCIBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; METHYLTRANSFERASES; REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84916233202     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2764     Document Type: Article

References (41)

1. Pober BR: Williams-Beuren syndrome. New Engl J Med 362: 239-252, 2010.
2. Bellugi U, Lichtenberger L, Mills D, Galaburda A and Korenberg JR: Bridging cognition, the brain and molecular genetics: evidence from Williams syndrome. Trends Neurosci 22: 197-207, 1999.
3. Morris CA, Demsey SA, Leonard CO, Dilts C and Blackburn BL: Natural history of Williams syndrome: physical characteristics. J Pediatr 113: 318-326, 1988.
4. Merla G, Ucla C, Guipponi M and Reymond A: Identifcation of additional transcripts in the Williams-Beuren syndrome critical region. Hum Genet 110: 429-438, 2002.
5. Doll A and Grzeschik KH: Characterization of two novel genes, WBSCR20 and WBSCR22, deleted in Williams-Beuren syndrome. Cytogenet Cell Genet 95: 20-27, 2001.
6. Cheng X: DNA modifcation by methyltransferases. Curr Opin Struct Biol 5: 4-10, 1995.
7. Takebayashi S, Tamura T, Matsuoka C and Okano M: Major and essential role for the DNA methylation mark in mouse embryogenesis and stable association of DNMT1 with newly replicated regions. Mol Cell Biol 27: 8243-8258, 2007.
8. Nakazawa Y, Arai H and Fujita N: The novel metastasis promoter Merm1/Wbscr22 enhances tumor cell survival in the vasculature by suppressing Zac1/p53-dependent apoptosis. Cancer Res 71: 1146-1155, 2011.
9. Tiedemann RE, Zhu YX, Schmidt J, et al: Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 72: 757-768, 2012.
10. Li H and Yang BB: Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin 34: 870-879, 2013.
11. Zhang X, Ding L and Sandford AJ: Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. BMC Mol Biol 6: 4, 2005.
12. Rho HW, Lee BC, Choi ES, et al: Identifcation of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR. BMC Cancer 10: 240, 2010.
13. Weglarz L, Molin I, Orchel A, Parfniewicz B and Dzierzewicz Z: Quantitative analysis of the level of p53 and p21(WAF1) mRNA in human colon cancer HT-29 cells treated with inositol hexa-phosphate. Acta Bioch Pol 53: 349-356, 2006.
14. Carmichael J, DeGraff WG, Gazdar A F, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
15. Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
16. Lin DL and Chang C: p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem 271: 14649-14652, 1996.
17. Vermeulen PB, Gasparini G, Fox SB, et al: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantifcation in solid human tumours. Eur J Cancer 38: 1564-1579, 2002.
18. Hendrix MJ, Wood WR, Seftor EA, et al: Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 50: 4121-4130, 1990.
19. Teng I W, Hou PC, Lee KD, et al: Targeted methylation of two tumor suppressor genes is suffcient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res 71: 4653-4663, 2011.
20. Kerr J F, Winterford CM and Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
21. Bak Y, Kim H, Kang JW, et al: A synthetic naringenin derivative, 5-hydroxy-7, 4'-diacetyloxyflavanone-N-phenyl hydrazone (N101-43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells. J Agric Food Chem 59: 10286-10297, 2011.
22. Kim TH, Seo WD, Ryu H W, et al: Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem Biol Interact 188: 111-118, 2010.
23. Rho JK, Choi YJ, Ryoo BY, et al: p53 enhances geftinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res 67: 1163-1169, 2007.
24. Lai SL, Perng RP and Hwang J: p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7: 64-70, 2000.
25. Kawasaki M, Nakanishi Y, Kuwano K, et al: The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemo-resistance in advanced non-small cell lung cancer. Clin Cancer Res 3: 1195-1200, 1997.
26. Kawasaki M, Nakanishi Y, Kuwano K, et al: Immunohisto-chemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34: 1352-1357, 1998.
27. Osaki M, Tatebe S, Goto A, et al: 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis 2: 221-226, 1997.
28. Li YX, Lin ZB and Tan HR: Wild type p53 increased chemo-sensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. Acta Pharmacol Sin 25: 76-82, 2004.
29. Yu ZW, Zhao P, Liu M, et al: Reversal of 5-fouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells. World J Gastroenterol 10: 1979-1983, 2004.
30. Liu HC, Chen GG, Vlantis AC, et al: 5-fuorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J 12: 482-493, 2006.
31. Liu Y, Xing H, Weng D, et al: Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Cancer Lett 274: 47-53, 2009.
32. Takeba Y, Sekine S, Kumai T, et al: Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 30: 1400-1406, 2007.
33. Takeba Y, Kumai T, Matsumoto N, et al: Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 104: 232-242, 2007.
34. Vaziri SA, Hill J, Chikamori K, et al: Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol Cancer Ther 4: 1880-1890, 2005.
35. Ueno M, Nonaka S, Yamazaki R, Deguchi N and Murai M: SN-38 induces cell cycle arrest and apoptosis in human testicular cancer. Eur Urol 42: 390-397, 2002.
36. Xie X, Sasai K, Shibuya K, et al: P53 status plays no role in radio-sensitizing effects of SN-38, a camptothecin derivative. Cancer Chemother Pharmacol 45: 362-368, 2000.
37. Osaki S, Nakanishi Y, Takayama K, et al: Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther 7: 300-307, 2000.
38. Boyer J, McLean EG, Aroori S, et al: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fuorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10: 2158-2167, 2004.
39. Oizumi S, Isobe H, Ogura S, et al: Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res 22: 4029-4037, 2002.
40. McDonald AC and Brown R: Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. Br J Cancer 78: 745-751, 1998.
41. Wang Y, Zhu S, Cloughesy TF, Liau LM and Mischel PS: p53 disruption profoundly alters the response of human glio-blastoma cells to DNA topoisomerase I inhibition. Oncogene 23: 1283-1290, 2004.